A Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study in Overweight/Obese Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (PEG)-BHD1028
Latest Information Update: 28 Aug 2024
At a glance
- Drugs (PEG) BHD1028 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors EncuraGen
Most Recent Events
- 28 Aug 2024 New trial record